Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire

BACKGROUND: Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and second-line treatments for uncomplicated falciparum malaria in Côte d’Ivo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Malar J
Main Authors: Toure, Offianan A, Assi, Serge B, N’Guessan, Tiacoh L, Adji, Gbessi E, Ako, Aristide B, Brou, Marie J, Ehouman, Marie F, Gnamien, Laeticia A, Coulibaly, M’Lanhoro AA, Coulibaly, Baba, Beourou, Sylvain, Bassinka, Issiaka, Soumahoro, Adama, Kadjo, Florence, Tano, Mea A
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4251865/
https://ncbi.nlm.nih.gov/pubmed/25409546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2875-13-439
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados